South Korea's Samsung Biologics signs $231 million supply deal with GSK

SEOUL (Reuters) - South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million(188.91 million pounds) with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.The biotech arm of Samsung Group will start with manufacturing drugs for autoimmune disease lupus for GSK with the aim to expand to making other drugs for the British drugmaker, an official at Samsung Biologics told Reuters."Samsung..